ArticleNature2024
Genetic determinants of micronucleus formation in vivo.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 44 citations in OpenAlex.
- DNA-PKcs and PARP1 at the interface between DNA damage responses and cGAS-STING signaling: context-dependent roles and therapeutic implications.Cancer biology & therapy · 2026Review
- A system-level metastable model of cancer evolution: integrating replication stress, cell cycle deregulation and chromosomal instability.Annals of medicine · 2026Review
- DNA damage in thyroid cancer patients treated with radioactive iodine in Johannesburg, South Africa.EJNMMI reports · 2026Article
- A mitochondrial insertion directs substrate selection and engagement by the protein unfoldase ClpX.The Journal of biological chemistry · 2026Article
- Hiding in plain sight: uncovering the genetic basis of complex phenotypes through low-risk groups.Genetics · 2026Article
- Microtubule binding protein Togaram1 is required for proper development of mammalian forebrain and neural primary cilia.Developmental biology · 2026Article
- MCM2 germline variants predispose to familial papillary thyroid carcinoma due to genomic instability caused by MCM complex disruption.Oncogene · 2026Article
- Machine learning-based gait classification and genome-wide association identify a QTL for gait type in Colombian paso horses.iScience · 2026Article
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- Article
- SIRT1: Protean roles at the nexus of health, disease, and therapeutics.Journal of cell communication and signaling · 2026Article
- Diversification of plant specific organellar single-stranded DNA binding genes and their roles in mitochondrial genome rearrangements in Arabidopsis and rice.BMC plant biology · 2026Article
- Adhesion G protein-coupled receptors.Pharmacological reviews · 2026Review
- Dysfunctional DNA Mismatch Repair Drives the Evolution of Gene Amplification in MTX-Resistant Human Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Exploring the shared genetic architecture between periodontitis and cardiovascular disease.BDJ open · 2026Article
- Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.Nature communications · 2026Article
- Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026Review
- Cis-regulatory evolution reveals sensory trade-offs as a genetic basis for temporal niche evolution in tapirs.Science advances · 2026Article
- A mitochondrial insertion directs substrate selection and engagement by ClpX.bioRxiv : the preprint server for biology · 2026Article
- A novel spliceosomopathy caused by de novo SF3B3 variants.Genome medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 9 institutions in 6 countries.
D J AdamsWellcome Sanger Institute, Cambridge, UK. da1@sanger.ac.uk.ORCID 0000-0001-9490-0306
B Barlas *UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.
R E McIntyre *Wellcome Sanger Institute, Cambridge, UK.
I SalgueroThe Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
L van der WeydenWellcome Sanger Institute, Cambridge, UK.ORCID 0000-0002-0645-1879
A BarrosWellcome Sanger Institute, Cambridge, UK.
J R VicenteUK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.
N KarimpourUK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.
A HaiderUK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.
M RanzaniWellcome Sanger Institute, Cambridge, UK.
G TurnerWellcome Sanger Institute, Cambridge, UK.
N A ThompsonWellcome Sanger Institute, Cambridge, UK.
V HarleWellcome Sanger Institute, Cambridge, UK.
R Olvera-LeónWellcome Sanger Institute, Cambridge, UK.
C D Robles-EspinozaWellcome Sanger Institute, Cambridge, UK.
A O SpeakWellcome Sanger Institute, Cambridge, UK.ORCID 0000-0003-4890-4685
N GeislerWellcome Sanger Institute, Cambridge, UK.
W J WeningerDivision of Anatomy, MIC, Medical University of Vienna, Wien, Austria.
S H GeyerDivision of Anatomy, MIC, Medical University of Vienna, Wien, Austria.ORCID 0000-0003-2283-4439
J HewinsonWellcome Sanger Institute, Cambridge, UK.
N A KarpWellcome Sanger Institute, Cambridge, UK.
Sanger Mouse Genetics Project
B FuWellcome Sanger Institute, Cambridge, UK.
F YangWellcome Sanger Institute, Cambridge, UK.
Z KozikFunctional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK.
J ChoudharyFunctional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK.ORCID 0000-0003-0881-5477
L YuFunctional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK.ORCID 0000-0001-8378-9112
M S van RuitenDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
B D RowlandDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-0694-8463
C J LelliottWellcome Sanger Institute, Cambridge, UK.
M Del Castillo Velasco-HerreraWellcome Sanger Institute, Cambridge, UK.ORCID 0000-0001-5956-0211
R VerstratenWellcome Sanger Institute, Cambridge, UK.
L BrucknerExperimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.
A G HenssenExperimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.ORCID 0000-0003-1534-778X
M A RooimansDepartment of Human Genetics, Section of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
J de LangeDepartment of Human Genetics, Section of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
T J MohunDivision of Developmental Biology, MRC, National Institute for Medical Research, London, UK.
M J ArendsDivision of Pathology, Cancer Research UK Scotland Centre, Institute of Genetics & Cancer The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-6826-8770
K A KentistouMRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
P A CoelhoDepartment of Genetics, University of Cambridge, Cambridge, UK.
Y ZhaoUK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.
H ZecchiniMetabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
J R B PerryMRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.ORCID 0000-0001-6483-3771
S P JacksonThe Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9317-7937
G BalmusWellcome Sanger Institute, Cambridge, UK. gb318@cam.ac.uk.ORCID 0000-0003-2872-4468
Wellcome Sanger Institute · GBUniversity of Cambridge · GBInstitute of Cancer Research · GBAmsterdam University Medical Centers · NLMedical University of Vienna · ATEdinburgh Cancer Research · GBGerman Cancer Research Center · DEMax Delbrück Center · DEThe Netherlands Cancer Institute · NL
Funding
Mouse Phenotyping Informatics Infrastruture - MP12U54HG006370 · NHGRI · EUROPEAN MOLECULAR BIOLOGY LABORATORY · PI BROWN, STEVE, FLICEK, PAUL · 2011 to 2015
$11.4MCancer Research UK 18795Cancer Research UK 18796Cancer Research UK CRI_CORE_LIMIC_2324Medical Research Council MC_UU_00006/2Medical Research Council MC_UU_12015/2NHGRI NIH HHS U54 HG006370Wellcome Trust 206388/Z/17/Z
Abstract
Genomic instability arising from defective responses to DNA damage
Indexed as
Genomic InstabilityMicronuclei, Chromosome-DefectiveAnimalsCarrier ProteinsCell Cycle ProteinsChondroitin Sulfate ProteoglycansChromosomal Proteins, Non-HistoneChromosomesDNA DamageHumansMiceNuclear ProteinsPhenotypeSirtuin 1Synthetic Lethal MutationsCarrier ProteinsCell Cycle ProteinsChondroitin Sulfate ProteoglycansChromosomal Proteins, Non-HistoneDSCC1 protein, humanNuclear ProteinsSIRT1 protein, humanSirtuin 1SMC3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.